Cafepharma Today

June 6 2025 - Novartis presses court for hasty decision in long-running Entresto patent feud with MSN
Novartis presses court for hasty decision in long-running Entresto patent feud with MSN
'Not a horse and pony show': At FDA cell and gene roundtable, officials look for ways to cut red tape
With ADCs on the rise, drugmakers embrace a new oncology pillar
Bayer trial combines two top drugs for kidney disease
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Are Big Pharma Investors Ignoring the Patent Cliff?
Motley Fool
Wednesday, September 26, 2012 - 11:01am
tags:
patents, patent cliff, Abbott Labs, Merck, Eli Lilly, Pfizer
Biogen's New Hemophilia Drug Could Replace Pfizer's Old One
Forbes
Wednesday, September 26, 2012 - 11:00am
tags:
hemophilia, Pfizer, BiogenIdec, factor IX, BeneFix
Battle Lines Drawn in the MS Market
Motley Fool
Wednesday, September 26, 2012 - 10:56am
tags:
multiple sclerosis, MS, BiogenIdec, BG-12, Sanofi, Aubagio, Gilenya, Novartis
Five-Cent Diabetes Pill From 1958 May Be New Cancer Drug
Bloomberg
Wednesday, September 26, 2012 - 10:27am
tags:
metformin, prostate cancer
Another Approval for Amgen's Prolia
Yahoo/Zacks
Tuesday, September 25, 2012 - 4:45pm
tags:
Amgen, Prolia, Merck, Eli Lilly, osteoporosis
Arena: DEA Schedule IV Will Make Belviq The Obesity Blockbuster Drug
Seeking Alpha
Tuesday, September 25, 2012 - 4:01pm
tags:
Arena Pharmaceuticals, Belviq, obesity
Achillion Pharma draws bullish bet
Yahoo/optionMONSTER
Tuesday, September 25, 2012 - 4:01pm
tags:
Achillion
J&J Pushed Risperdal With Golf, Popcorn, Witness Says
Bloomberg
Tuesday, September 25, 2012 - 3:59pm
tags:
JNJ, Risperdal, antipsychotics
An 80% Plunge Leads the Biotech Bloodbath
Motley Fool
Tuesday, September 25, 2012 - 12:41pm
tags:
Peregrine Pharmaceuticals, Vertex Pharmaceuticals, Questcor, Arena Pharmaceuticals, Vivus
Obesity In America Likely To Set Up Arena And Vivus For Big Gains
TheStreet.com
Tuesday, September 25, 2012 - 12:37pm
tags:
Arena Pharmaceuticals, Vivus, obesity, Qsymia, Belviq
Vertex Advances One of Two Hep C Drugs
TheStreet.com
Tuesday, September 25, 2012 - 12:35pm
tags:
Vertex Pharmaceuticals, hepatitis C, ALS-2200, ALS-2158, nucleoside polymerase inhibitor
Wild-Eyed Optimism About Horizon's Plummet
Motley Fool
Tuesday, September 25, 2012 - 12:01pm
tags:
Horizon Pharma
Bristol-Myers Squibb And The Promise Of Cancer Immunotherapy
Seeking Alpha
Tuesday, September 25, 2012 - 11:53am
tags:
Bristol-Myers Squibb, melanoma, Yervoy
Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data
TheStreet.com
Tuesday, September 25, 2012 - 11:37am
tags:
Celgene, Abraxane, pancreatic cancer
Biomarin: Four Clinical Trial Events to Watch Before Year End
TheStreet.com
Tuesday, September 25, 2012 - 11:27am
tags:
Biomarin, BMN-111, GALNs, BMRN-763, Peg-Pal
Cosmo Pharma CEO Sees $1.5 Billion Dye Luring Buyer by 2013
Bloomberg
Tuesday, September 25, 2012 - 11:15am
tags:
Cosmo Pharma, M&A
New CEO at GenVec slashes jobs but shelters Novartis partnership
Fierce Biotech
Tuesday, September 25, 2012 - 11:06am
tags:
GenVec, layoffs, Novartis
1 Pharma That's Failing Forward
Motley Fool
Tuesday, September 25, 2012 - 11:03am
tags:
Astex, amuvatinib, Dacogen
Scientists Rank Genzyme Among Best Employers
Yahoo
Tuesday, September 25, 2012 - 11:02am
tags:
Genzyme
How Many Pharmas Does It Take to Accelerate Drug Development?
Motley Fool
Tuesday, September 25, 2012 - 10:04am
tags:
drug development, Abbott Labs, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GSK, JNJ, Pfizer, Roche, Sanofi, TransCelerate BioPharma

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Cleaning Up the Medical Literature
In the Pipeline
Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.